Core Viewpoint - Vison Pharma-B (02561) has seen a stock price increase of nearly 4%, currently trading at 44.68 HKD, driven by positive developments in its product pipeline and strategic partnerships [1] Group 1: Product Development - The fastest progressing product in Vison Pharma's pipeline is Long-Acting Growth Hormone, expected to receive domestic approval in the second half of 2025, potentially becoming the third long-acting growth hormone approved in China [1] - The company currently has two unique products: Napeptide and Parapeptide, with the latter anticipated to submit a market application by the end of 2025 [1] Group 2: Strategic Partnerships - In June, Vison Pharma entered into a collaboration with WuXi Biologics to advance localized production, aiming to provide cost-effective and high-value products to meet domestic clinical needs [1] - In July, the company partnered with Anke Bio to jointly promote the commercialization of its products, indicating a promising market outlook [1]
港股异动 | 维昇药业-B(02561)再涨近4% 隆培促生长素有望年内获批上市 公司持续推进商业化进程